Richard Fang was appointed as Interim Chief Executive Officer at Picard Medical, Inc..
“The Board appointed Richard Fang, Ph.D., 60, as the Company's Interim Chief Executive Officer, effective as of the Separation Date.”
Picard Medical, Inc. — fact timeline
Source-grounded facts extracted from Picard Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Patrick NJ Schnegelsberg resigned as Chief Executive Officer and Director at Picard Medical, Inc..
“On June 17, 2026, Patrick NJ Schnegelsberg notified Picard Medical, Inc. (the "Company") of his decision to step down as Chief Executive Officer and as a member of the Board of Directors of the Company (the "Board"), effective June 18, 2026”
Georgina Smith was appointed as Chief Accounting Officer at Picard Medical, Inc..
“The Board of Directors of the Company appointed Georgina Smith, 54, as the Company’s Chief Accounting Officer, effective June 1, 2026.”
Bernard Skaggs was terminated as Chief Financial Officer at Picard Medical, Inc..
“Bernard Skaggs was terminated as the Chief Financial Officer of Picard Medical, Inc. (the “Company”), effective immediately.”
Picard Medical, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.2 million, net income $7.6 million.
“Revenue grew 85% to $1.2 million for the first quarter of 2026”
Picard Medical, Inc. received a nyse_american deficiency notice notice regarding other (rules 1003(a)(ii)).
“reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the”
Picard Medical, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i)).
“May 15, 2026, the Company received a written notice (the “May 15 Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standar”
Picard Medical, Inc. entered into Placement Agency Agreement with WestPark Capital, Inc. valued at 7.0% of the gross proceeds of the Offering (effective 2026-05-05).
“WestPark Capital, Inc. acted as the sole placement agent (the “Placement Agent”) in connection with the Offering pursuant to a placement agency agreement, dated May 5, 2026, by and between the Company and the Placement Agent (the “Placement Agency Agreement”).”
Picard Medical, Inc. entered into Purchase Agreement with certain investors valued at aggregate of approximately $5.0 million (effective 2026-05-05).
“Certain of the investors purchased their Offered Shares and Common Warrants pursuant to a securities purchase agreement dated May 5, 2026 by and among the Company and such investors (the “ Purchase Agreement ”).”
Picard Medical, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).
“May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of”
Picard Medical, Inc. entered into Warrant Issuance and Exchange Agreement with holder (the “Holder”) (effective 2026-05-05).
“On May 5, 2026, Picard Medical, Inc. (the “Company”) entered into a Warrant Issuance and Exchange Agreement (the “Exchange Agreement”) with the holder (the “Holder”) of certain of the Company’s outstanding warrants to purchase shares of the Company’s common stock”
Picard Medical, Inc. reported first quarter ended March 31, 2026 results: revenue $1.1 million.
“Revenue rose 79.9% to $1.1 million for the three months ended March 31, 2026, from $0.6 million for the three months ended March 31, 2025”
Picard Medical, Inc. issued 80,128 shares of the Company’s common stock of common stock to Quick Capital, LLC.
“the issuance and sale of a convertible promissory note in the principal face amount of $555,555.56 (the “Note”) and 80,128 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as origination shares (the “Origination Shares”).”
Picard Medical, Inc. issued principal face amount of $555,555.56 of convertible note to Quick Capital, LLC for $490,000.00.
“issued with an original issue discount of $55,555.56, resulting in an aggregate funded amount of $500,000.00. The cash consideration delivered to the Company at the closing was $490,000.00, after giving effect to the original issue discount and $10,000.00 withheld and directed for the Buyer’s expenses. The Note bears a one-time interest charge of twelve percent, or”
Picard Medical, Inc. incurred convertible notes of $555,555.56 with Quick Capital, LLC at twelve percent maturing nine (9) months from the Issue Date.
“On April 7, 2026, Picard Medical, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Quick Capital, LLC, a Wyoming limited liability company (the “Buyer”), an accredited investor, for the issuance and sale of a convertible promissory note in the principal face amount of $555,555.56 (the “Note”)”
Picard Medical, Inc. entered into Purchase Agreement with Quick Capital, LLC valued at $555,555.56 (effective 2026-04-07).
“On April 7, 2026, Picard Medical, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Quick Capital, LLC, a Wyoming limited liability company (the “Buyer”), an accredited investor, for the issuance and sale of a convertible promissory note in the principal face amount of $555,555.56”
Picard Medical, Inc. reported the year ended December 31, 2025 results: revenue $4.94 million, net income $(27.0) million.
“be available shortly after the call on the Company’s website, picardmedical.com, and continue to be available for 60 days. Financial Results Revenue Total revenue for 2025 was $4.94 million, compared to $4.39 million in 2024, representing an increase of 12.5 percent. Product revenue was $4.75 million, while rental revenue was $0.19 million. Product revenue was”
Picard Medical, Inc. issued 7,009,346 shares of common stock of warrant to institutional investor.
“the Company also issued the Initial Warrants to purchase up to 7,009,346 shares of Common Stock”
Picard Medical, Inc. entered into engagement letter with WestPark Capital, Inc..
“In connection with the Private Placement, the Company entered into an engagement letter with WestPark Capital, Inc. (“WestPark”), pursuant to which WestPark acted as the Company’s exclusive placement agent.”
Picard Medical, Inc. entered into Security Agreement (effective 2025-12-26).
“In connection with the Purchase Agreement and the issuance of the Notes, (i) the Company entered into a Security Agreement, dated as of the Initial Closing (the “Security Agreement”), pursuant to which the Company granted a first-priority security interest in substantially all of the tangible and intangible assets of the Company and certain of its US subsidiaries, subject to permitted liens and exceptions, to secure the Company’s Obligations (as defined in the Security Agreement) under the Note Documents (as defined in the Security Agreement) and related transaction documents”
Picard Medical, Inc. entered into Notes with a single institutional investor valued at an aggregate principal amount of $15,000,000 (effective 2025-12-26).
“On December 26, 2025 (the “Initial Closing”), the Company, pursuant to the Purchase Agreement, issued the Initial Purchased Notes (as defined in the Purchase Agreement) in an aggregate principal amount of $15,000,000, as the first draw under a notes facility.”
Picard Medical, Inc. entered into Purchase Agreement with a single institutional investor (effective 2025-12-24).
“On December 24, 2025, Picard Medical, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Buyer”), pursuant to which the Company agreed to issue and sell, in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D, promulgated thereunder (the “Private Placement”): (i) senior secured notes of the Company due December 26, 2028 (the “Notes”) and (ii) warrants (the “Warrants” and together with the Notes, the “Securities”) to purchase 7,009,346 shares of the Company’s common stock”
Picard Medical, Inc. incurred senior notes of $15,000,000 at 0.00% maturing December 26, 2028.
“On December 26, 2025 (the “Initial Closing”), the Company, pursuant to the Purchase Agreement, issued the Initial Purchased Notes (as defined in the Purchase Agreement) in an aggregate principal amount of $15,000,000, as the first draw under a notes facility.”
Picard Medical, Inc. incurred loan of $1,000,000 with Fang Family Fund, LLC at 6% per annum, compounded annually maturing November 27, 2026.
“On November 26, 2025 (the " Effective Date "), Picard Medical, Inc., a Delaware corporation (the " Company ") entered into a short-term bridge financing in the form of an unsecured promissory note (the " Note ") with Fang Family Fund, LLC (" FFF I "), an affiliate of Mr. Richard Fang, the Chairman of the Company’s Board of Directors (the " Board "), pursuant to which FFF I agreed to lend the Company an aggregate principal amount of $1,000,000 (the " Principal Amount ").”
Picard Medical, Inc.: Amended and Restated Bylaws were adopted and became effective (effective 2025-08-28).
“On August 28, 2025, the Company’s Amended and Restated Bylaws (the “ A&R Bylaws ”), in substantially the form previously filed as Exhibit 3.6 to the Registration Statement, were adopted by the Company and became effective.”
Picard Medical, Inc.: Second Amended and Restated Certificate of Incorporation became effective (effective 2025-08-28).
“On August 28, 2025, the Company’s Second Amended and Restated Certificate of Incorporation (the “ Second A&R Charter ”), in substantially the form previously filed as Exhibit 3.5 to the Registration Statement was filed with the Secretary of State of the State of Delaware and became effective.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.